Abstract: Targeted radioimmunotherapy of malignant tumors and their metastases have been paid more and more attention, and have become a major exploration area of therapeutic nuclear medicine. The radiopharmaceuticals for radioimmunotherapy can serve as targeted carriers of radionuclides to malignant tumors, meanwhile decrease the damage to non-targeted normal tissues. Due to the in-vivo deiodination of ¹³¹I labelled monoclonal antibodies (MoAbs), the application of metal radionuclides plays a more important role in the development of radiolabelled MoAbs. The current status of the development of metal radionuclides labelled MoAbs for radioimmunotherapy in three aspects: metal radionuclides, bifunctional chelating agents and radiopharmaceuticals for radioimmunotherapy were summarized.